Novel investigative approaches for advanced renal cell carcinoma Review uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • Metastatic renal cell carcinoma remains one of the most treatment-resistant malignancies in humans. As such, long-term survival is limited to a minority of patients. Interferon-alpha and interleukin-2 induced major responses in some patients with renal cell carcinoma, and in so doing generated a great deal of interest and hope. However, clinical benefit is limited to relatively few patients. Here, we briefly discuss the management of metastatic renal cell carcinoma, and then elaborate on several novel treatment approaches in development, including retinoids, monoclonal antibodies, and antiangiogenesis strategies.

publication date

  • April 26, 2000

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 10768602

Additional Document Info

start page

  • 234

end page

  • 9

volume

  • 27

number

  • 2